Otsuka buying Avanir for $3.5B

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) will acquire Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) for $3.5 billion, or $17 per share. The

Read the full 207 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE